Abbott Laboratories (NYSE:ABT) posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company’s Covid-19 testing equipment, beating the consensus of $10.18 billion.

SEKISUI Diagnostics, a global medical diagnostics manufacturer, has formalized an exclusive distribution agreement with Aptitude Medical Systems (Aptitude™), an innovative developer of decentralized molecular diagnostics, to sell the Aptitude MetrixTM COVID-19 Test in the U.S. The Metrix test is currently the only EUA approved, molecular test which can be used with both swab and saliva samples and can performed by healthcare professionals or at home by consumers.

Virax Biolabs said on Thursday that it has formed an alliance with the University of Manchester and Northern Care Alliance Foundation Trust, a member organization of the UK's National Health Service, to investigate T-cell responses in long COVID-19 patients.

Siemens Healthineers reported Wednesday that its non-COVID-19 revenues rose about 11 percent year over year on a comparable basis in its fiscal fourth quarter with strong growth in its Varian Medical Systems and imaging segments, along with low-single-digit growth in its diagnostics segment.

Group sales grow by 1% at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter.

It is stated that from 30 August 2023, all travelers entering China will no longer need to undergo any COVID-19 testing.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.

Laboratory Corporation of America reported on Thursday that its second quarter revenues grew 4 percent year over year, including a 13 percent gain in its base business, which excludes COVID-19 testing revenues.

DiaSorin said on Thursday that its second quarter revenues fell around 12 percent year over year on a constant currency basis, as it experienced an expected continued sharp decline in COVID-19 testing, partially offset by improvements in other immunodiagnostics sales.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)